Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and valuation cuts.

Dr. James H. Bekker made it clear while standing at a podium in front of the U.S. Food and Drug Administration (FDA) in ...